Alnylam (ALNY) Q1 2024: TTR Franchise Up 29% as Helios B Readout Nears Pivotal Moment

2024-05-02 | By EarningsIQ Research

Alnylam’s TTR franchise delivered 29% growth, propelling overall portfolio momentum ahead of the critical Helios B Phase III readout. Robust execution across rare and prevalent disease programs is positioning the company for a potential inflection in both label expansion and pipeline breadth. Investors now turn to late June for the Helios B outcome, which will define Alnylam’s near-term trajectory and capital allocation strategy.

Summary

• Cardiomyopathy Expansion: Helios B data readout is set to reshape Alnylam’s market scope and strategic direction.
• Pipeline Velocity: Nine proprietary INDs and 15 total by 2025 signal a doubling of clinical programs.
• Commercial Leverage: Operating gains and SG&A discipline highlight the drive toward self-sustainability.

Business Overview

Alnylam is a biotechnology company focused on developing and commercializing RNA interference (RNAi) therapeutics, a modality that silences disease-causing genes. The company’s revenue is driven by four wholly owned commercial products spanning rare diseases (Givlaari, Oxlumo) and TTR amyloidosis (Onpattro, Amvuttra), with a growing pipeline targeting both rare and prevalent conditions such as hypertension and neurodegeneration. Alnylam also generates revenue from collaborations, licensing, and royalties with partners including Roche and Regeneron.

Performance Analysis

Alnylam’s Q1 product revenue reached $365 million, up 32% year-over-year, reflecting robust demand across both TTR and rare disease franchises. The TTR segment, anchored by Amvuttra and Onpattro, delivered $264 million, marking 29% growth and now represents over 70% of total product revenue. U.S. TTR sales rose 35% YoY, driven by accelerating Amvuttra uptake and physician adoption, while international markets saw 23% growth despite price headwinds in Germany post free-pricing period.

The rare disease portfolio, led by Givlaari and Oxlumo, grew 40% YoY, with Givlaari up 21% and Oxlumo revenue surging 77% on strong demand and favorable partner timing. Collaboration revenue spiked 225% YoY—primarily from Roche milestone payments and Regeneron partnership expansion—while royalty income climbed 63%. Gross margin remained high at 85%, but management cautioned that rising Amvuttra royalties will pressure margins in subsequent quarters. Operating leverage improved materially, with SG&A growth held below revenue growth and a swing to non-GAAP operating gain.

• TTR Franchise Growth: U.S. Amvuttra adoption and international launches are expanding the addressable patient base.
• Rare Disease Upside: Oxlumo’s 94% growth in rest-of-world markets benefited from timing, but Q2 sales are expected to normalize.
• Collaboration Windfall: Roche milestone revenue and Regeneron expansion provided a significant boost to total revenue.

Alnylam’s financial profile is increasingly resilient, but margin headwinds and normalization of collaboration revenue will test whether top-line momentum can sustain profit trajectory through 2024.

Executive Commentary

Strategic Positioning

1. Helios B as a Strategic Inflection Point

The Helios B Phase III study is the linchpin for Alnylam’s near-term value creation. Success would enable Amvuttra’s label expansion into cardiomyopathy, targeting both hereditary and wild-type ATTR, and unlock a much larger addressable market. Management’s statistical plan enhancements and focus on hard outcomes (death, hospitalization) aim to maximize differentiation and regulatory competitiveness.

2. TTR Franchise Market Leadership

Amvuttra’s rapid adoption and robust prescriber growth reflect effective commercial execution and strong clinical differentiation. The brand’s flexibility (hospital, outpatient, home dosing) and >99% patient access, combined with a branded awareness campaign, are expanding the diagnosed patient pool. Notably, 80% of global HATTR-PN patients remain undiagnosed or untreated, underscoring significant runway.

3. Pipeline Acceleration and Portfolio Diversification

Alnylam’s pipeline velocity is accelerating, with plans for nine proprietary IND filings and 15 total (including partners) by end of 2025. The Zarbisiran hypertension program is progressing rapidly, with positive Phase II results and a newly initiated Cardio 3 study targeting high CV risk patients. CNS and extrahepatic programs, including Alzheimer’s and cerebral amyloid angiopathy, add further breadth and optionality.

4. Capital Discipline and Operating Leverage

SG&A and R&D expense growth were held below revenue growth, yielding improved operating leverage and a non-GAAP operating profit. Management reaffirmed that current guidance already incorporates Helios B launch investment, highlighting disciplined capital allocation even as the company ramps for potential expansion.

5. Partnership Monetization

Collaboration and royalty revenue are increasingly material, with Roche and Regeneron partnerships delivering milestone and recurring income. These non-product revenue streams enhance cash flow and de-risk pipeline investment, but are subject to timing variability.

Key Considerations

This quarter’s results set the stage for a potentially transformative second half, but several factors warrant close investor attention:

• Helios B Readout as Value Catalyst: The upcoming data release will determine Amvuttra’s market expansion and shape Alnylam’s capital allocation for pipeline and infrastructure.
• Margin Compression Risk: Higher Amvuttra royalties and normalization of collaboration revenue could pressure gross and operating margins despite top-line growth.
• Patient Finding and Diagnosis: With 80% of the global HATTR-PN population undiagnosed, commercial success hinges on effective awareness and diagnostic campaigns.
• Pipeline Execution Pace: Delivering on the promise of nine proprietary INDs and advancing CNS programs will be critical for sustaining long-term growth.

Risks

The Helios B outcome is a binary risk that could reshape Alnylam’s revenue and R&D priorities. Failure would force pipeline reprioritization and potentially delay profitability. Gross margin erosion from rising royalties and potential price concessions, especially as Amvuttra faces international reimbursement pressure, could weigh on future earnings. Competition from TTR stabilizers (tafamidis) and the challenge of patient identification in underdiagnosed populations remain persistent headwinds. Pipeline execution risk is elevated given the ambitious IND schedule and expansion into new therapeutic areas.

Forward Outlook

For Q2 2024, Alnylam guided to:

• Continued revenue growth, with Q1 establishing a strong baseline for meeting or exceeding full-year targets.
• Normalization of Oxlumo sales after Q1 timing benefits in international markets.

For full-year 2024, management reiterated guidance:

• Net product revenue: $1.4–$1.5 billion (13%–21% YoY growth)
• Collaboration and royalty revenue: $325–$425 million
• Combined non-GAAP R&D and SG&A: $1.675–$1.775 billion (9% growth at midpoint)

Management highlighted the upcoming Helios B readout (late June/early July) as the pivotal milestone, with a quiet period to begin May 13. Pipeline catalysts include multiple trial initiations in CNS, diabetes, and oncology.

• Helios B outcome will dictate commercial and R&D investment pacing.
• Progress on Zarbisiran and CNS programs will inform pipeline optionality and capital allocation.

Takeaways

Alnylam’s commercial and pipeline execution is robust, but the Helios B readout will define the company’s next strategic act.

• Helios B as Value Driver: Success would expand Amvuttra’s label, unlock a larger market, and cement Alnylam’s leadership in RNAi-based cardiovascular therapeutics.
• Pipeline and Capital Discipline: Management is balancing aggressive pipeline expansion with measured SG&A and R&D spend, supporting a path to self-sustainability.
• Watch for Execution on Patient Finding: Sustained growth depends on driving diagnosis and access in underpenetrated rare and prevalent disease populations.

Conclusion

Alnylam delivered a strong start to 2024, with commercial momentum and pipeline breadth positioning the company for a pivotal inflection. The Helios B data will determine whether Alnylam can convert operational strength into durable market leadership and pipeline-fueled growth.

Industry Read-Through

Alnylam’s results highlight the growing commercial viability of RNAi therapeutics in both rare and common diseases, setting a benchmark for peer companies in genetic medicine. The Helios B outcome will shape the competitive landscape for TTR amyloidosis, influencing payer dynamics, pricing, and combination therapy strategies across the sector. Pipeline acceleration and disciplined capital allocation signal a maturing biotech model that other platform companies may seek to emulate, especially as they scale from rare disease into larger indications. Strategic focus on patient identification and access will remain a key theme for specialty pharma and biotech as precision medicines move into broader populations.

ALNY Healthcare Biotechnology RNAi Rare Disease Cardiomyopathy Pipeline Collaboration